Ligand Binding Mass Spectrometric Immunoassay (LB-MSIA™) Workflow with Deglycosylation for Therapeutic Antibodies

This application note illustrates how pre-analytical deglycosylation of the antibody decreases data complexity and increases sensitivity that further improves upon the LB-MSIA work flow; a pre-clinical bio-analytical solution, based on mass spectrometric detection, specific for the bioanalysis of humanized and fully human therapeutic monoclonal antibodies using adalimumab in rodent plasma as a model biological system.